Bausch Health Companies Inc. has announced an increase in shareholding by its chairperson of the board, John A. Paulson. Paulson Capital Inc. and certain affiliates and managed funds have acquired the net long position of 34,721,118 common shares previously held by Mr. Carl C. Icahn and his affiliates. Based on information provided, Paulson Capital Inc. and certain affiliates and managed funds now beneficially own approximately 19.13% of the company’s outstanding common shares.
Furthermore, the director appointment and nomination agreement between the company and Icahn Group has been terminated, leading to the resignation of Brett M. Icahn and Steven D. Miller from the board of directors. John A. Paulson expressed confidence in the company’s efforts to maximize shareholder value and highlighted the promising business prospects in both Bausch Health and its subsidiary, Bausch + Lomb Corporation.
Bausch Health Companies Inc., a global pharmaceutical company, is listed on the NYSE and TSX. The company's primary product range spans across gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, through its controlling interest in Bausch + Lomb Corporation. As a result of these announcements, the company's shares have moved 11.05% on the market, and are now trading at a price of $8.34. If you want to know more, read the company's complete 8-K report here.
